Efecto antihipertensivo del valsartán: Estudio multicéntrico nacional
Background: Valsartan is an angiotensin AT1 receptor antagonist. Clinical studies have shown that this is an effective and well tolerated drug. Aim: To compare valsartan with other commonly used antihypertensives in a National multicentric study. Material and methods: Between 1997 and 1998, a pharma...
Guardado en:
| Autor principal: | |
|---|---|
| Lenguaje: | Spanish / Castilian |
| Publicado: |
Sociedad Médica de Santiago
2000
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000500004 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:scielo:S0034-98872000000500004 |
|---|---|
| record_format |
dspace |
| spelling |
oai:scielo:S0034-988720000005000042004-06-22Efecto antihipertensivo del valsartán: Estudio multicéntrico nacionalPrat M.,Hernán Angiotensins Hypertension Valsartan Background: Valsartan is an angiotensin AT1 receptor antagonist. Clinical studies have shown that this is an effective and well tolerated drug. Aim: To compare valsartan with other commonly used antihypertensives in a National multicentric study. Material and methods: Between 1997 and 1998, a pharmacological surveillance of patients with mild or moderate hypertension, coming from different regions of the country, was carried out. Patients were followed during 8 weeks. In the group treated with valsartan, the initial dose was 80 mg/day. After four weeks of therapy, and according to patient's response the dose of valsartan or of the other antihypertensives was modified. Results: Five hundred ninety three patients, aged 59 years old as a mean, were included in the study. Of these 434 (265 female) received valsartan and 159 (101 female) other antihypertensive drugs. Fifteen percent of patients treated with valsartan and 25% of patients with other medications required a dose change at four weeks, due to lack of response (p < 0.01). At week eight, 1.5% of patients with valsartan and 17.4% of patients with other medications reported adverse effects such as cough, headache, edema or flushing (p < 0.01). Conclusions: In this Chilean observational multicentric study, valsartan proved to be more effective and to cause less adverse effects than commonly used medications in hypertensive patients. (Rev Méd Chile 2000; 128: 475-82)info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.128 n.5 20002000-05-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000500004es10.4067/S0034-98872000000500004 |
| institution |
Scielo Chile |
| collection |
Scielo Chile |
| language |
Spanish / Castilian |
| topic |
Angiotensins Hypertension Valsartan |
| spellingShingle |
Angiotensins Hypertension Valsartan Prat M.,Hernán Efecto antihipertensivo del valsartán: Estudio multicéntrico nacional |
| description |
Background: Valsartan is an angiotensin AT1 receptor antagonist. Clinical studies have shown that this is an effective and well tolerated drug. Aim: To compare valsartan with other commonly used antihypertensives in a National multicentric study. Material and methods: Between 1997 and 1998, a pharmacological surveillance of patients with mild or moderate hypertension, coming from different regions of the country, was carried out. Patients were followed during 8 weeks. In the group treated with valsartan, the initial dose was 80 mg/day. After four weeks of therapy, and according to patient's response the dose of valsartan or of the other antihypertensives was modified. Results: Five hundred ninety three patients, aged 59 years old as a mean, were included in the study. Of these 434 (265 female) received valsartan and 159 (101 female) other antihypertensive drugs. Fifteen percent of patients treated with valsartan and 25% of patients with other medications required a dose change at four weeks, due to lack of response (p < 0.01). At week eight, 1.5% of patients with valsartan and 17.4% of patients with other medications reported adverse effects such as cough, headache, edema or flushing (p < 0.01). Conclusions: In this Chilean observational multicentric study, valsartan proved to be more effective and to cause less adverse effects than commonly used medications in hypertensive patients. (Rev Méd Chile 2000; 128: 475-82) |
| author |
Prat M.,Hernán |
| author_facet |
Prat M.,Hernán |
| author_sort |
Prat M.,Hernán |
| title |
Efecto antihipertensivo del valsartán: Estudio multicéntrico nacional |
| title_short |
Efecto antihipertensivo del valsartán: Estudio multicéntrico nacional |
| title_full |
Efecto antihipertensivo del valsartán: Estudio multicéntrico nacional |
| title_fullStr |
Efecto antihipertensivo del valsartán: Estudio multicéntrico nacional |
| title_full_unstemmed |
Efecto antihipertensivo del valsartán: Estudio multicéntrico nacional |
| title_sort |
efecto antihipertensivo del valsartán: estudio multicéntrico nacional |
| publisher |
Sociedad Médica de Santiago |
| publishDate |
2000 |
| url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000500004 |
| work_keys_str_mv |
AT pratmhernan efectoantihipertensivodelvalsartanestudiomulticentriconacional |
| _version_ |
1718435916577505280 |